Direvo Biotech has announced that it has raised €10.5m (US$) in its Series B equity financing.
Go deeper with GlobalData
Direvo describes itself as a leading company in screening-based directed evolution, applying its integrated proprietary technologies to the development of better biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. The company was established in the year 2000 and collaborates with companies such as Danisco, Novozymes and Evotec OAI.
With Danisco Venture, Copenhagen, as lead investor and TVM (Techno Venture Management), Munich, as co-lead investor, the Cologne-based German biotechnology company Direvo Biotech has raised €10.5m in new equity capital in its Series B financing.
Further investors in this round are SK Kapitalbeteiligungsgesellschaft Köln, New York based Sanders Morris Harris and the private investors Nobel laureate Prof. Manfred Eigen, Dr Ruthild Winkler-Oswatitsch, Prof. Heinrich M. Schulte as well as all other investors from the Series A financing.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
